A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters

Paolo Leombruni, Andrea Pierò, Annalisa Brustolin, Valeria Mondelli, Maura Levi, Stefania Campisi, Susanna Marozio, Giovanni Abbate-Daga, Secondo Fassino

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalHuman Psychopharmacology
Volume21
Issue number3
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Binge-Eating Disorder
Sertraline
Bulimia
Psychopathology
Therapeutics
Feeding Behavior
Psychiatry
Comorbidity
Weight Loss
Outpatients
Eating
Weights and Measures

Keywords

  • Binge eating disorder
  • Drugs
  • Eating disorders
  • Obesity
  • Sertraline

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Leombruni, P., Pierò, A., Brustolin, A., Mondelli, V., Levi, M., Campisi, S., ... Fassino, S. (2006). A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Human Psychopharmacology, 21(3), 181-188. https://doi.org/10.1002/hup.758

A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. / Leombruni, Paolo; Pierò, Andrea; Brustolin, Annalisa; Mondelli, Valeria; Levi, Maura; Campisi, Stefania; Marozio, Susanna; Abbate-Daga, Giovanni; Fassino, Secondo.

In: Human Psychopharmacology, Vol. 21, No. 3, 04.2006, p. 181-188.

Research output: Contribution to journalArticle

Leombruni, P, Pierò, A, Brustolin, A, Mondelli, V, Levi, M, Campisi, S, Marozio, S, Abbate-Daga, G & Fassino, S 2006, 'A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters', Human Psychopharmacology, vol. 21, no. 3, pp. 181-188. https://doi.org/10.1002/hup.758
Leombruni, Paolo ; Pierò, Andrea ; Brustolin, Annalisa ; Mondelli, Valeria ; Levi, Maura ; Campisi, Stefania ; Marozio, Susanna ; Abbate-Daga, Giovanni ; Fassino, Secondo. / A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. In: Human Psychopharmacology. 2006 ; Vol. 21, No. 3. pp. 181-188.
@article{86cafbdc22c442d2877cc44afe3f9ea7,
title = "A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters",
abstract = "Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.",
keywords = "Binge eating disorder, Drugs, Eating disorders, Obesity, Sertraline",
author = "Paolo Leombruni and Andrea Pier{\`o} and Annalisa Brustolin and Valeria Mondelli and Maura Levi and Stefania Campisi and Susanna Marozio and Giovanni Abbate-Daga and Secondo Fassino",
year = "2006",
month = "4",
doi = "10.1002/hup.758",
language = "English",
volume = "21",
pages = "181--188",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters

AU - Leombruni, Paolo

AU - Pierò, Andrea

AU - Brustolin, Annalisa

AU - Mondelli, Valeria

AU - Levi, Maura

AU - Campisi, Stefania

AU - Marozio, Susanna

AU - Abbate-Daga, Giovanni

AU - Fassino, Secondo

PY - 2006/4

Y1 - 2006/4

N2 - Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.

AB - Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.

KW - Binge eating disorder

KW - Drugs

KW - Eating disorders

KW - Obesity

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=33646370985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646370985&partnerID=8YFLogxK

U2 - 10.1002/hup.758

DO - 10.1002/hup.758

M3 - Article

C2 - 16625525

AN - SCOPUS:33646370985

VL - 21

SP - 181

EP - 188

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 3

ER -